Dr. Reddy’s forays into HRT with acquisition of 2 brands from U.K. firm

Dr. Reddy’s Laboratories has acquired the trademarks of specialty brands Progynova and Cyclo-Progynova and related assets for India from the U.K.-headquartered Mercury Pharma Group.

The acquisition strengthens its gynaecology portfolio and marks introduction into the hormone replacement therapy (HRT) segment, Dr. Reddy’s said connected Wednesday.

Progynova (estradiol valerate) is an oral HRT indicated for attraction of estrogen deficiency symptoms and for prevention of postmenopausal osteoporosis. Cyclo-Progynova (estradiol valerate and norgestrel) is simply a combined HRT indicated for the attraction of estrogen deficiency symptoms, providing some estrogen and progestogen components.

Progynova is the fig 1 marque successful the Estradiol represented pharmaceutical market, with beardown doc equity and marque callback successful India. The marque recorded income of ₹100 crore, the Hyderabad-headquartered drugmaker said, citing IQVIA MAT December 2025 numbers.

“The acquisition volition service arsenic the spearhead of our enlargement into the HRT segment, strengthening our existing gynaecology portfolio successful India,” CEO-Branded Markets (India and Emerging Markets) M.V. Ramana said.